Mix and match = better patient satisfaction

Article

Mixing and matching the ReZoom (AMO) and Tecnis (AMO) multifocal intraocular lenses (IOLs) produces enhanced visual outcomes and patient satisfaction.

Mixing and matching the ReZoom (AMO) and Tecnis (AMO) multifocal intraocular lenses (IOLs) produces enhanced visual outcomes and patient satisfaction, according to Baha Toygar and colleagues from the Dunya Eye Hospital, Istanbul, Turkey.

In a concurrent case series, 11 refractive lens exchange (RLE) patients and three cataract patients were bilaterally implanted with ReZoom in the dominant eye and Tecnis in the fellow eye. One subject with high hyperopia underwent a piggyback IOL implantation. The target refraction for both multifocal IOLs was emmetropia.

At six-month follow-up, mean postoperative spherical equivalent (SE) was -0.11±0.47 D. Monocular uncorrected and best corrected distance visual acuity (VA) was 0.78±0.21 and 0.95±0.16, respectively. All patients, except for the patient receiving the piggyback implantation, could read 20/20 binocularly. Eighty-two percent of subjects achieved a near uncorrected VA of J2 or better and, when tested binocularly without correction, 100% of patients could read J2 or better, including 65% who achieved J1 or better. None of the patients reported halos or glare.

The researchers concluded from their study that the combination of the two lenses leads to enhanced visual outcomes and patient satisfaction.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.